JP2019526561A5 - - Google Patents

Download PDF

Info

Publication number
JP2019526561A5
JP2019526561A5 JP2019510788A JP2019510788A JP2019526561A5 JP 2019526561 A5 JP2019526561 A5 JP 2019526561A5 JP 2019510788 A JP2019510788 A JP 2019510788A JP 2019510788 A JP2019510788 A JP 2019510788A JP 2019526561 A5 JP2019526561 A5 JP 2019526561A5
Authority
JP
Japan
Prior art keywords
formulation
alkylene
composition
alkyl
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019510788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526561A (ja
JP6898429B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/098575 external-priority patent/WO2018036498A1/en
Publication of JP2019526561A publication Critical patent/JP2019526561A/ja
Publication of JP2019526561A5 publication Critical patent/JP2019526561A5/ja
Application granted granted Critical
Publication of JP6898429B2 publication Critical patent/JP6898429B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019510788A 2016-08-24 2017-08-23 黄斑変性症を治療するためのエンタカポン関連化合物 Active JP6898429B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016096472 2016-08-24
CNPCT/CN2016/096472 2016-08-24
PCT/CN2017/098575 WO2018036498A1 (en) 2016-08-24 2017-08-23 Entacapone-related compounds to treat macular degeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021013670A Division JP7116202B2 (ja) 2016-08-24 2021-01-29 黄斑変性症を治療するための医薬の製造におけるエンタカポン関連化合物の使用

Publications (3)

Publication Number Publication Date
JP2019526561A JP2019526561A (ja) 2019-09-19
JP2019526561A5 true JP2019526561A5 (enExample) 2020-07-16
JP6898429B2 JP6898429B2 (ja) 2021-07-07

Family

ID=61245496

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019510788A Active JP6898429B2 (ja) 2016-08-24 2017-08-23 黄斑変性症を治療するためのエンタカポン関連化合物
JP2021013670A Active JP7116202B2 (ja) 2016-08-24 2021-01-29 黄斑変性症を治療するための医薬の製造におけるエンタカポン関連化合物の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021013670A Active JP7116202B2 (ja) 2016-08-24 2021-01-29 黄斑変性症を治療するための医薬の製造におけるエンタカポン関連化合物の使用

Country Status (7)

Country Link
US (1) US10980766B2 (enExample)
EP (1) EP3503883B1 (enExample)
JP (2) JP6898429B2 (enExample)
CN (1) CN109689042B (enExample)
AU (1) AU2017317129B2 (enExample)
CA (1) CA3034547C (enExample)
WO (1) WO2018036498A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532976B2 (en) * 2015-06-23 2020-01-14 National Institute Of Biological Sciences, Beijing FTO inhibitors
CA3034547C (en) * 2016-08-24 2021-04-13 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
KR20210021299A (ko) 2018-05-10 2021-02-25 리제너론 파아마슈티컬스, 인크. 고농도 vegf 수용체 융합 단백질 함유 제제
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
JP2024518143A (ja) * 2021-04-15 2024-04-25 ブラウン ユニバーシティ ニトロフェニル－アクリルアミドおよびその使用
CN119546566A (zh) * 2022-07-29 2025-02-28 瑞璞鑫(苏州)生物科技有限公司 Fto抑制剂
WO2025162358A1 (en) * 2024-01-30 2025-08-07 Rpxds Co., Ltd Fto inhibitors of bicyclic structures
WO2025162373A1 (en) * 2024-01-30 2025-08-07 National Institute Of Biological Sciences, Beijing Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI864875A0 (fi) 1986-11-28 1986-11-28 Orion Yhtymae Oy Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa.
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TW200817315A (en) * 2006-06-16 2008-04-16 Sanol Arznei Schwarz Gmbh Entacapone-derivatives
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
EP1978014A1 (en) 2007-04-02 2008-10-08 Esteve Quimica, S.A. Process for the preparation of entacapone and intermediates thereof
WO2009003226A1 (en) * 2007-06-29 2009-01-08 Clarencew Pty Ltd Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration
AU2009236078B2 (en) * 2008-04-18 2014-03-06 Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona Methods and compositions for treating age-related macular degeneration
KR20110071064A (ko) * 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
EP2558104A4 (en) * 2010-04-12 2013-12-11 R Tech Ueno Ltd METHOD AND OPHTHALMIC COMPOSITION FOR TREATING RETINAL DISEASE
US20150031655A1 (en) * 2011-04-15 2015-01-29 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
ES2858511T3 (es) * 2012-10-17 2021-09-30 Exonate Ltd Compuestos útiles para tratar neovascularización ocular
CN103845317B (zh) 2012-11-28 2018-05-08 北京生命科学研究所 恩他卡朋在预防或治疗肥胖等代谢综合征中的应用
US20160317474A1 (en) * 2013-12-18 2016-11-03 Emory University Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects
JP6858712B2 (ja) * 2015-01-30 2021-04-14 リーバー インスティテュート フォー ブレイン ディベロップメントＬｉｅｂｅｒ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｒａｉｎ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｔ阻害方法及び組成物
CA2975401A1 (en) * 2015-01-30 2016-08-04 Lieber Institute For Brain Development Comt inhibiting methods and compositions
WO2016206573A1 (en) 2015-06-23 2016-12-29 National Institute Of Biological Sciences, Beijing Fto inhibitors
CA3034547C (en) 2016-08-24 2021-04-13 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration

Similar Documents

Publication Publication Date Title
JP2019526561A5 (enExample)
Crash-2 Collaborators The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial
CN114008035A (zh) 一种shp2磷酸酶变构抑制剂
JP2018521092A5 (enExample)
Roy et al. The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials
Szaliński et al. Fusarium keratitis—review of current treatment possibilities
JP2018523689A5 (enExample)
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
JP2007513190A5 (enExample)
JP2011528713A5 (enExample)
JP2019515908A5 (enExample)
JP2013508279A5 (enExample)
Hassan et al. Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: significance for melanoma treatment
JP2019530713A5 (enExample)
JP2020523356A5 (enExample)
JP2019507764A5 (enExample)
RU2018101473A (ru) Депо-препарат, содержащий сложный эфир лимонной кислоты
ES2405323T3 (es) Tratamiento de melanoma
Maccari et al. Can allostery be a key strategy for targeting PTP1B in drug discovery? A lesson from Trodusquemine
ES2924728T3 (es) Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas
JP2020510045A5 (enExample)
Zhang et al. Noncovalent bile acid oligomers as facial amphiphilic antimicrobials
CA2608163A1 (en) Hydralazine compositions and methods
RU99121654A (ru) Средства для предотвращения или лечения болезней, связанных с чрезмерной пролиферацией эпителиальных пигментных клеток сетчатки
JP2021502379A5 (enExample)